Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections

[en] Background: Acute respiratory infections (ARIs) comprise of a large and heterogeneous group of infections including bacterial, viral, and other aetiologies. In recent years, procalcitonin (PCT), a blood marker for bacterial infections, has emerged as a promising tool to improve decisions about antibiotic therapy (PCT-guided antibiotic therapy). Several randomised controlled trials (RCTs) have demonstrated the feasibility of using procalcitonin for starting and stopping antibiotics in different patient populations with ARIs and different settings ranging from primary care settings to emergency departments, hospital wards, and intensive care units. However, the effect of using procalcitonin on clinical outcomes is unclear. This is an update of a Cochrane review and individual participant data meta-analysis first published in 2012 designed to look at the safety of PCT-guided antibiotic stewardship. Objectives: The aim of this systematic review based on individual participant data was to assess the safety and efficacy of using procalcitonin for starting or stopping antibiotics over a large range of patients with varying severity of ARIs and from different clinical settings. Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE, and Embase, in February 2017, to identify suitable trials. We also searched ClinicalTrials.gov to identify ongoing trials in April 2017. Selection criteria: We included RCTs of adult participants with ARIs who received an antibiotic treatment either based on a procalcitonin algorithm (PCT-guided antibiotic stewardship algorithm) or usual care. We excluded trials if they focused exclusively on children or used procalcitonin for a purpose other than to guide initiation and duration of antibiotic treatment. Data collection and analysis: Two teams of review authors independently evaluated the methodology and extracted data from primary studies. The primary endpoints were all-cause mortality and treatment failure at 30 days, for which definitions were harmonised among trials. Secondary endpoints were antibiotic use, antibiotic-related side effects, and length of hospital stay. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using multivariable hierarchical logistic regression adjusted for age, gender, and clinical diagnosis using a fixed-effect model. The different trials were added as random-effects into the model. We conducted sensitivity analyses stratified by clinical setting and type of ARI. We also performed an aggregate data meta-analysis. Main results: From 32 eligible RCTs including 18 new trials for this 2017 update, we obtained individual participant data from 26 trials including 6708 participants, which we included in the main individual participant data meta-analysis. We did not obtain individual participant data for four trials, and two trials did not include people with confirmed ARIs. According to GRADE, the quality of the evidence was high for the outcomes mortality and antibiotic exposure, and quality was moderate for the outcomes treatment failure and antibiotic-related side effects. Primary endpoints: there were 286 deaths in 3336 procalcitonin-guided participants (8.6%) compared to 336 in 3372 controls (10.0%), resulting in a significantly lower mortality associated with procalcitonin-guided therapy (adjusted OR 0.83, 95% CI 0.70 to 0.99, P = 0.037). We could not estimate mortality in primary care trials because only one death was reported in a control group participant. Treatment failure was not significantly lower in procalcitonin-guided participants (23.0% versus 24.9% in the control group, adjusted OR 0.90, 95% CI 0.80 to 1.01, P = 0.068). Results were similar among subgroups by clinical setting and type of respiratory infection, with no evidence for effect modification (P for interaction > 0.05). Secondary endpoints: procalcitonin guidance was associated with a 2.4-day reduction in antibiotic exposure (5.7 versus 8.1 days, 95% CI -2.71 to -2.15, P < 0.001) and lower risk of antibiotic-related side effects (16.3% versus 22.1%, adjusted OR 0.68, 95% CI 0.57 to 0.82, P < 0.001). Length of hospital stay and intensive care unit stay were similar in both groups. A sensitivity aggregate-data analysis based on all 32 eligible trials showed similar results. Authors' conclusions: This updated meta-analysis of individual participant data from 12 countries shows that the use of procalcitonin to guide initiation and duration of antibiotic treatment results in lower risks of mortality, lower antibiotic consumption, and lower risk for antibiotic-related side effects. Results were similar for different clinical settings and types of ARIs, thus supporting the use of procalcitonin in the context of antibiotic stewardship in people with ARIs. Future high-quality research is needed to confirm the results in immunosuppressed patients and patients with non-respiratory infections. © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Disciplines :

Anesthesia & intensive care

Author, co-author :

Schuetz, Philipp; Kantonsspital Aarau, Medical University Department, Aarau, Switzerland, Kantonsspital Aarau, Department of Endocrinology/Metabolism/Clinical Nutrition, Department of Internal Medicine, Aarau, Switzerland, University of Basel, Medical Faculty, Basel, Switzerland

Wirz, Yannick; Kantonsspital Aarau, Medical University Department, Aarau, Switzerland

Sager, R.; Kantonsspital Aarau, Medical University Department, Aarau, Switzerland

Christ-Crain, M.; University Hospital Basel, University of Basel, Clinic for Endocrinology, Diabetes and Metabolism, Department of Clinical Research, Petersgraben 4, Basel, Switzerland

Stolz, D.; University Hospital Basel, Clinic of Pneumology and Pulmonary Cell Research, Petersgraben 4, Basel, Switzerland

Tamm, M.; University Hospital Basel, Clinic of Pneumology and Pulmonary Cell Research, Petersgraben 4, Basel, Switzerland

Bouadma, L.; Hôpital Bichat-Claude Bernard, Université Paris 7-Denis-Diderot, Service de Réanimation Médicale, Paris, France

Luyt, C. E.; Groupe Hospitalier Pitie-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Paris 6-Pierre-et-Marie-Curie, Service de Réanimation Médicale, Paris, France

Wolff, M.; Université Paris 7-Denis-Diderot, Service de Réanimation Médicale, Hôpital Bichat-Claude-Bernard, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

Chastre, J.; Université Paris 6-Pierre-et-Marie-Curie, Service de Réanimation Médicale, Hôpital PitiéSalpêtrière (AP-HP), Paris, France

More authors (31 more)

Language :

English

Title :

Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections

Publication date :

2017

Journal title :

Cochrane Database of Systematic Reviews

ISSN :

1361-6137

eISSN :

1469-493X

Publisher :

John Wiley and Sons Ltd

Volume :

2017

Issue :

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 16 January 2018

Statistics

Number of views

87 (5 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Annane D, Maxime V, Faller JP, Mezher C, Clec'h C, Martel P, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open 2013;3(2):pii: e002186. 6761978
Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Internal Medicine 2016;176(9):1266-76. 6761980
Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375(9713):463-74. 2975454
Branche AR, Walsh EE, Vargas R, Hulbert B, Formica MA, Baran A, et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. Journal of Infectious Diseases 2015;212(11):1692-700. 6761982
Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Archives of Internal Medicine 2008;168(18):2000-7. 2975456
Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. European Respiratory Journal 2010;36(3):601-7. 2975458
Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay M, Huber P, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;1363(9409):600-7. 2975460
Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. American Journal of Respiratory and Critical Care Medicine 2006;174(1):84-93. 2975462
Corti C, Fally M, Fabricius-Bjerre A, Mortensen K, Jensen BN, Andreassen HF, et al. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. International Journal of Chronic Obstructructive Pulmonary Disease 2016;11:1381-9. [DOI: 10.2147/COPD.S104051]6761984
De Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infectious Diseases 2016;16(7):819-27. 6761986
Deliberato RO, Marra AR, Sanches PR, Martino MD, Ferreira CE, Pasternak J, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagnostic Microbiology and Infectious Disease 2013;76(3):266-71. 6761988
Ding J, Chen Z, Feng K. Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. International Journal of Medical Sciences 2013;10(7):903-7. 6761990
Hochreiter M, Kohler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care 2009;13(3):R83. 2975464
Kristoffersen KB, Sogaard OS, Wejse C, Black FT, Greve T, Tarp B, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission - a randomized trial. Clinical Microbiology and Infection 2009;15(5):481-7. 2975466
Layios N, Lambermont B, Canivet JL, Morimont P, Preiser JC, Garweg C, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Critical Care Medicine 2012;40(8):2304-9. 6761992
Lima SS, Nobre V, de Castro Romanelli RM, Clemente WT, da Silva Bittencourt HN, Melo AC, et al. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Annals of Hematology 2016;95(7):1169-76. 6761994
Long W, Deng XQ, Tang JG, Xie J, Zhang YC, Zhang Y, et al. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community acquired pneumonia. Zhonghua Nei Ke Za Zhi 2009;48(3):216-9. 2975468
Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community acquired pneumonia. Respirology 2011;76(1):266-9. 2975470
Long W, Li LJ, Huang GZ, Zhang XM, Zhang YC, Tang JG, et al. Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12-month follow-up. Critical Care 2014;18(5):471. 6761996
Maravić-Stojković V, Laušević-Vuk L, Jović M, Ranković A, Borzanović M, Marinković J. Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial. Srpski Arhiv Celokupno Lekarstvo 2011;139(11-12):736-42. 6761997
Najafi A, Khodadadian A, Sanatkar M, Shariat Moharari R, Etezadi F, Ahmadi A, et al. The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit. Acta Medica Iranica 2015;53(9):562-7. 6761999
Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine 2009;177(5):498-505. 2975472
Ogasawara T, Umezawa H, Naito Y, Takeuchi T, Kato S, Yano T, et al. Procalcitonin-guided antibiotic therapy in aspiration pneumonia and an assessment of the continuation of oral intake. Respiratory Investigation 2014;52(2):107-13. 6762001
Oliveira CF, Botoni FA, Oliveira CR, Silva CB, Pereira HA, Serufo JC, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Critical Care Medicine 2013;41(10):2336-43. 6762003
Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Archives of Surgery 2009;394(2):221-6. 2975474
Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302(10):1059-66. 2975476
Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, et al. ProGUARD Study Investigators, ANZICS Clinical Trials Group. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine 2014;190(10):1102-10. 6762005
Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131(1):9-19. 2975478
Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. European Respiratory Journal 2009;34(6):1364-75. 2975480
Tang J, Long W, Yan L, Zhang Y, Xie J, Lu G, et al. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC Infectious Diseases 2013;13:596. [DOI: 10.1186/1471-2334-13-596]6762007
Verduri A, Luppi F, D'Amico R, Balduzzi S, Vicini R, Liverani A, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS ONE 2015;10(3):e0118241. 6762009
Wang JX, Zhang SM, Li XH, Zhang Y, Xu ZY, Cao B. Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. International Journal of Infectious Diseases 2016;48:40-5. [DOI: 10.1016/j.ijid.2016.04.024]6762011
Dharaniyadewi D, Lie KC, Sukmana N, Rumende CM. Effect of semi-quantitative procalcitonin assay on the adequacy of empirical antibiotics and mortality in septic patients. Citical Care 2013;17(Suppl 4):P15. 6762013
Esposito S, Tagliabue C, Picciolli I, Semino M, Sabatini C, Consolo S, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respiratory Medicine 2011;105(12):1939-45. 2975482
Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Critical Care Medicine 2011;39(7):1792-9. 2975484
Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Critical Care Medicine 2011;39(9):2048-58. 2975486
Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Annals of Emergency Medicine 2007;50(1):34-41. 2975488
Kook JL, Chao SR, Le J, Robinson PA. Impact of the use of procalcitonin assay in hospitalised patients with pneumonia at a community care hospital. Infection Control and Hospital Epidemiology 2012;33(4):424-6. 2975490
Liew YX, Chlebicki MP, Lee W, Hsu LY, Kwa AL. Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP). European Journal of Clinical Microbiology and Infectious Diseases 2011;30:853-5. 2975492
Liu BH, Li HF, Lei Y, Zhao SX, Sun ML. Clinical significance of dynamic monitoring of procalcitonin in guiding the use of antibiotics in patients with sepsis in ICU. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2013;25(11):690-3. 6762015
Qu R, Ji Y, Ling Y, Ye CY, Yang SM, Liu YY, et al. Procalcitonin is a good tool to guide duration of antibiotic therapy in patients with severe acute pancreatitis. A randomized prospective single-center controlled trial. Saudi Medical Journal 2012;33(4):382-7. 2975496
Saeed K, Dryden M, Bourne S, Paget C, Proud A. Reduction in antibiotic use through procalcitonin testing in patients in the medical admission unit or intensive care unit with suspicion of infection. Journal of Hospital Infection 2011;78(4):289-92. 2975498
Schuetz P, Batschwaroff M, Dusemund F, Albrich W, Burgi U, Maurer M, et al. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. European Journal of Clinical Microbiology and Infectious Diseases 2010;29(3):269-77. 2975500
Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clinical Trials 2005;2(3):209-17. 2975502
Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clinical Infectious Diseases 2004;39(2):206-17. 2975504
Stocker M, Fontana M, el Helou S, Wegscheider K, Berger TM. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology 2010;97(2):165-74. 2975506
Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infectious Diseases 2007;7(3):210-7. 2975508
Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009;37(6):497-507. 2975510
Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Critical Care Medicine 2006;34(7):1996-2003. 2975512
NCT02130986. Procalcitonin Antibiotic Consensus Trial (ProACT). clinicaltrials.gov/ct2/show/study/NCT02130986 First received: May 1, 2014. 6762017
NCT02261610. Pulmonary Embolism and PCT. PE-PCT Study. clinicaltrials.gov/ct2/show/NCT02261610 First received: September 5, 2014. 6762019
NCT02332577. Study to compare the efficacy of pristinamycin (Pyostacine) versus amoxicillin in the treatment of acute community acquired pneumonia. clinicaltrials.gov/ct2/show/NCT02332577 First received: January 5, 2015. 6762021
NCT02440828. Addition of tobramycin inhalation in the treatment of ventilator associated pneumonia (VAPORISE). clinicaltrials.gov/ct2/show/NCT02440828 First received: March 13, 2015. 6762023
NCT02787603. Procalcitonin in Early Antibiotic Interruption in Patient With Bacterial Pulmonary infeCtion and Acute Heart Failure (EPICAD). clinicaltrials.gov/ct2/show/NCT02787603 First received: May 25, 2016. 6762025
NCT02862314. PROcalcitonin Pneumonia/Pneumonitis Associated With ASPIration (PROPASPI). clinicaltrials.gov/ct2/show/NCT02862314 First received: July 29, 2016. 6762027
NCT02931409. Intraoperative PEEP optimization: effects on postoperative pulmonary complications and inflammatory response. clinicaltrials.gov/ct2/show/NCT02931409 First received: October 5, 2016. 6762029
Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter post-study survey (ProREAL). Archives of Internal Medicine 2012;172(9):715-22.
Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003539.pub2]
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.
Balk RA, Kadri SS, Cao Z, Robinson SB, Lipkin C, Bozzette SA. Effect of procalcitonin testing on health-care utilization and costs in critically ill patients in the United States. Chest 2017;151(1):23-33.
Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ 2009;338:b1374.
Doan Q, Enarson P, Kissoon N, Klassen TP, Johnson DW. Rapid viral diagnosis for acute febrile respiratory illness in children in the Emergency Department. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD006452.pub4]
Drozdov D, Schwarz S, Kutz A, Grolimund E, Rast AC, Steiner D, et al. Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial. BMC Medicine 2015;13(1):104.
Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 2002;359(9318):1648-54.
Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997;278(11):901-4.
Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365(9435):579-87.
GRADE Working Group, McMaster University. GRADEpro GDT. Version (accessed April 2017). Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hoare Z, Lim WS. Pneumonia: update on diagnosis and management. BMJ 2006;332(7549):1077-9.
Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld AB. The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. Clinical Microbiology and Infection 2015;21(5):474-81.
Konstantinides S. Clinical practice. Acute pulmonary embolism. New England Journal of Medicine 2008;359(26):2804-13.
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine 2006;34(6):1589-96.
Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009;136(5):1237-48.
Kutz A, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Critical Care (London, England) 2015;19(1):74.
Kutz K, Hausfater P, Oppert M, Alan M, Grolimund E, Gast C, et al. Comparison between B·R·A·H·M·S PCT direct, a new sensitive point-of-care testing device for rapid quantification of procalcitonin in emergency department patients and established reference methods - a prospective multinational trial. Clinical Chemistry and Laboratory Medicine 2016;54(4):577-84.
Lawrence KL, Kollef MH. Antimicrobial stewardship in the intensive care unit: advances and obstacles. American Journal of Respiratory and Critical Care Medicine 2009;179(6):434-8.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009;62(10):e1-34.
Liberati A, D'Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD000022.pub3]
Manzano S, Bailey B, Girodias JB, Galetto-Lacour A, Cousineau J, Delvin E. Impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial. American Journal of Emergency Medicine 2010;28(6):647-53.
Meili M, Muller B, Kulkarni P, Schutz P. Management of patients with respiratory infections in primary care: procalcitonin, C-reactive protein or both?. Expert Review of Respiratory Medicine 2015;9(5):587-601.
Meili M, Kutz A, Briel M, Christ-Crain M, Bucher HC, Mueller B, et al. Infection biomarkers in primary care patients with acute respiratory tract infections - comparison of procalcitonin and C-reactive protein. BMC Pulmonary Medicine 2016;16(1):43.
Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Critical Care Medicine 2000;28(4):977-83.
Muller B, Becker KL. Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Medical Weekly 2001;131(41-2):595-602.
Muller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010;138(1):121-9.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sager R, Kutz A, Mueller B, Schuetz P. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Medicine 2017;15(1):15.
Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine 2011;171(15):1322-31.
Schuetz P, Aujesky D, Muller C, Muller B. Biomarker-guided personalised emergency medicine for all - hope for another hype?. Swiss Medical Weekly 2015;145:w14079.
Schuetz P, Daniels LB, Kulkarni P, Anker SD, Mueller B. Procalcitonin: a new biomarker for the cardiologist. International Journal of Cardiology 2016;223:390-7. [DOI: 10.1016/j.ijcard.2016.08.204]
Schuetz P, Birkhahn R, Sherwin R, Jones AE, Singer A, Kline JA, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin monitoring sepsis (MOSES) study. Critical Care Medicine 2017;45(5):781-9.
Spurling GKP, Del Mar CB, Dooley L, Foxlee R. Delayed antibiotics for respiratory infections. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD004417.pub3]
StataCorp LP. Stata Statistical Software: Release 12.1. College Station (TX): StataCorp LP, 2005.
Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement. JAMA 2015;313(16):1657-65.
Stojanovic I, Schneider JE, Wei L, Hong Z, Keane C, Schuetz P. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective. Clinical Chemistry and Laboratory Medicine 2017;55(4):561-70.
Thompson SG, Turner RM, Warn DE. Multilevel models for meta-analysis, and their application to absolute risk differences. Statistical Methods in Medical Research 2001;10(6):375-92.
Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2000;19(24):3417-32.
van Vugt SF, Broekhuizen BD, Lammens C, Zuithoff NP, de Jong PA, Coenen S, et al. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ 2013;346:f2450.
Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infectious Diseases 2013;13(5):426-35.
Zaas AK, Garner BH, Tsalik EL, Burke T, Woods CW, Ginsburg GS. The current epidemiology and clinical decisions surrounding acute respiratory infections. Trends in Molecular Medicine 2014;20(10):579-88.
Schuetz P, Briel M, Christ-Crain M, Wolbers M, Stolz D, Tamm M, et al. Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews 2008, Issue 10. [DOI: 10.1002/14651858.CD007498]
Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Review of Anti-Infective Therapy 2010;8(5):575-87.
Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine 2011;171(15):1322-31.
Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD007498.pub2]